Find the full Prescribing Information here.

The STEP trial was the first-ever study assessing the efficacy and safety of the capsaicin 8% topical system for patients living with painful diabetic peripheral neuropathy (PDPN) of the feet. Here to share key findings from the trial and what this treatment might mean for our patients are Dr. David M. Simpson, principal investigator of the STEP trial, and Dr. Rory Abrams, an expert neurologist and author of a recent high-concentration capsaicin 8% topical system review paper.

QUTENZA® is a registered trademark of Averitas Pharma, Inc.
© 2021 Averitas Pharma, Inc. All rights reserved.
M-QZA-US-01-21-0048 June 2021

Small cell lung cancer (SCLC) is a highly aggressive, lethal, and widely metastatic lung cancer. While therapeutic progress in SCLC has been limited over the years, immunotherapy has made some meaningful advancements in the treatment landscape. Joining Dr. Jennifer Caudle to discuss key diagnostic and therapeutic considerations such as TECENTRIQ® (atezolizumab) for 1L ES-SCLC, is Dr. Tracey Evans, Director of Thoracic Oncology Research at Lankenau Institute for Medical Research and Co-Director of the Thoracic Oncology Program at Main Line Health.

This program is intended for US Physicians.

M-US-00010802(v1.0)

The presence of multiple disorders of the cardio-renal-metabolic (CRM) systems can increase the risk of morbidity in patients. In this video, Drs. Peter McCullough and Rachel Pessah-Pollack will discuss the coexistence of CRM disorders, their impact on the continuum of disease risk, and the collaborative care approach to managing these interconnected disorders.

This is part 2 of a 3-part podcast series. Please listen to podcast 1 before listening to this podcast.

Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69643-D (06/2021)

Coexistence of cardio-renal-metabolic (CRM) disorders may increase the risk of mortality in patients. Here Drs. Peter McCullough and Rachel Pessah-Pollack discuss the effects of coexisting CRM disorders on cardiovascular mortality and overall life expectancy, as well as how a collaborative care approach could improve patient outcomes.

This is part 3 of a 3-part podcast series. Please listen to podcasts 1 and 2 before listening to this podcast.

Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69643-E (06/2021)

We often think about the cardiovascular, renal, and metabolic (CRM) systems as separate entities, but it's essential that we keep the interconnected nature of these systems top of mind. Drs. Rachel Pessah-Pollack and Peter McCullough are here to review the shared risk factors that contribute to the development and progression of comorbid conditions within these systems, the impact of coexisting conditions of the CRM systems, the continuum of risk, and more.

This is part 1 of a 3-part podcast series.

Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69643-C (06/2021)

Drs. Eden Miller and James O'Keefe discuss how cardiovascular risk factors can impact patients with type 2 diabetes and provide an overview of resources to help HCPs manage the disease.

This is part 2 of a 3-part podcast series. Please listen to podcast 1 before listening to this podcast.

Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69642-D (06/2021)

Learn about the cardiovascular complications associated with type 2 diabetes, how cardiovascular safety became a focus in the management of type 2 diabetes, and more, with Drs. Eden Miller and James O'Keefe.

This is part 1 of a 3-part podcast series.

Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69642-C (06/2021)

To get a better understanding of the impact of cardiovascular disease on patients with type 2 diabetes, join Drs. Eden Miller and James O'Keefe as they discuss how concurrent diabetes and cardiovascular disease can significantly affect life expectancy.

This is part 3 of a 3-part podcast series. Please listen to podcasts 1 and 2 before listening to this podcast.

Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69642-E (06/2021)

Not only is hepatocellular carcinoma (HCC) the most common primary liver cancer in adults, but it’s also the fastest-growing cause of cancer-related deaths in the US. That’s why Dr. Joel Wedd, Associate Professor of Medicine at the Virginia Commonwealth University and Medical Director of Liver Transplant at the Hume-Lee Transplant Center, is here to discuss the pathogenesis of hepatocellular carcinoma, risk factors, the importance of early-stage detection, and more.

Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.